Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease

Table 1 Small interfering RNA therapies

Target gene	Delivery system	Administration	Ref.
TNF-α siRNA therapy with delivery system
TNF-α	TKN	Oral	[14]
TNF-α	PEI-PVA	Oral	[15]
TNF-α	NiMOS	Oral	[16]
TNF-α	OMe-P	Oral	[17]
TNF-α	TPP-PPM	Ex vivo	[18]
TNF-α	Fab'-bearing PLA-PEG	Oral	[19]
siRNA therapy targeting other molecules with delivery system
CyD1	Abs to β7 integrin	Intravenous	[22]
TNF-α/CyD1	NiMOS	Oral	[23]
Map4k4	β1,3-D-glucan shell	Oral	[24]
CD98	scCD98-functionalized	Oral	[25]

SiRNA: Small interfering RNA; TKN: Thioketal nanoparticle; PEI-PVA: Polyethyleneimine/polyvinyl alcohol; NiMOS: Nanoparticles-in-microspheres oral system; OMe-P: 2’-O-methyl and propanediol modification; TPP-PPM: Mannosylated bioreducible cationic polymer/sodium triphosphate; Fab'-bearing PLA-PEG: Polylactic acid-polyethylene glycol copolymer/Fab' portion of the F4/80 Ab; scCD98-functionalized: Chitosan-alginate hydrogel/single-chain CD98 Abs.